NCT05040932View on ClinicalTrials.gov

Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

July 16, 2023

Study Completion Date

July 16, 2023

Conditions
Cancer
Interventions
DRUG

YH004

IV infusion once every 3 weeks (Q3W).

Trial Locations (3)

2145

Westmead Hospital, Sydney

2217

Southside Cancer Care Centre, School of Medicine, University of Wollongong, Wollongong

3144

Cabrini Health Limited, Malvern East

All Listed Sponsors
lead

Eucure (Beijing) Biopharma Co., Ltd

INDUSTRY